Cargando…

Hidradenitis Suppurativa (HS) prevalence, demographics and management pathways in Australia: A population-based cross-sectional study

BACKGROUND: Hidradenitis Suppurativa (HS) is a painful, chronic inflammatory skin disease. Global estimates of prevalence vary between 0.03% and 4% of the population. Our main aim was to determine HS prevalence in the Australian adult population focussing on the demographics, management pathways and...

Descripción completa

Detalles Bibliográficos
Autores principales: Calao, Miriam, Wilson, Jodie L., Spelman, Lynda, Billot, Laurent, Rubel, Diana, Watts, Alan D., Jemec, Gregor B. E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057625/
https://www.ncbi.nlm.nih.gov/pubmed/30040827
http://dx.doi.org/10.1371/journal.pone.0200683
_version_ 1783341561328697344
author Calao, Miriam
Wilson, Jodie L.
Spelman, Lynda
Billot, Laurent
Rubel, Diana
Watts, Alan D.
Jemec, Gregor B. E.
author_facet Calao, Miriam
Wilson, Jodie L.
Spelman, Lynda
Billot, Laurent
Rubel, Diana
Watts, Alan D.
Jemec, Gregor B. E.
author_sort Calao, Miriam
collection PubMed
description BACKGROUND: Hidradenitis Suppurativa (HS) is a painful, chronic inflammatory skin disease. Global estimates of prevalence vary between 0.03% and 4% of the population. Our main aim was to determine HS prevalence in the Australian adult population focussing on the demographics, management pathways and diagnosis rate of individuals living with HS. METHODS: In this population-based cross-sectional study, 17,050 individuals representative of the Australian adult population were asked through face-to-face household interviews to answer a previously validated HS screening questionnaire with high diagnostic power. Individuals who screened positive were asked additional questions, including previous diagnosis of HS and number/type of physicians consulted regarding their condition. RESULTS: 11,433 Australian residents answered the HS questionnaire, 88 screening positive for HS (0.77%; 95% CI 0.62–0.95). Considering the previously reported sensitivity (0.97) and positive predictive value (0.85) of the screening questionnaire, HS prevalence was estimated to be 0.67% (95% CI 0.53%-0.84%). 6 of 88 suspected HS individuals reported a pre-existing HS diagnosis (6.8%; 95% CI 3.2%-14.1%). 25.6% of the undiagnosed individuals suspected of having HS had not seen any clinicians regarding their boils; the remaining ones had consulted General Practitioners (96.7%), and clinicians from different specialties. Comparisons of individuals who screened positive for HS versus those who screened negative demonstrated statistically significant differences in gender (p = 0.0046), age (p<0.0001), BMI (p = 0.0307), smoking status (p<0.0001), employment status (p<0.0001) and income (p = 0.0321). CONCLUSIONS: The prevalence of HS in Australia was estimated to be 0.67% (95% CI 0.53%-0.84%). The diagnosis rate amongst the suspected HS cases was low, which appeared to be due to a combination of patients not seeking help and decentralization of care. Individuals suspected of having HS were more likely to be females, young, obese, smokers, unemployed or at home duties and having lower annual personal income in comparison with individuals not suspected of having HS.
format Online
Article
Text
id pubmed-6057625
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-60576252018-08-06 Hidradenitis Suppurativa (HS) prevalence, demographics and management pathways in Australia: A population-based cross-sectional study Calao, Miriam Wilson, Jodie L. Spelman, Lynda Billot, Laurent Rubel, Diana Watts, Alan D. Jemec, Gregor B. E. PLoS One Research Article BACKGROUND: Hidradenitis Suppurativa (HS) is a painful, chronic inflammatory skin disease. Global estimates of prevalence vary between 0.03% and 4% of the population. Our main aim was to determine HS prevalence in the Australian adult population focussing on the demographics, management pathways and diagnosis rate of individuals living with HS. METHODS: In this population-based cross-sectional study, 17,050 individuals representative of the Australian adult population were asked through face-to-face household interviews to answer a previously validated HS screening questionnaire with high diagnostic power. Individuals who screened positive were asked additional questions, including previous diagnosis of HS and number/type of physicians consulted regarding their condition. RESULTS: 11,433 Australian residents answered the HS questionnaire, 88 screening positive for HS (0.77%; 95% CI 0.62–0.95). Considering the previously reported sensitivity (0.97) and positive predictive value (0.85) of the screening questionnaire, HS prevalence was estimated to be 0.67% (95% CI 0.53%-0.84%). 6 of 88 suspected HS individuals reported a pre-existing HS diagnosis (6.8%; 95% CI 3.2%-14.1%). 25.6% of the undiagnosed individuals suspected of having HS had not seen any clinicians regarding their boils; the remaining ones had consulted General Practitioners (96.7%), and clinicians from different specialties. Comparisons of individuals who screened positive for HS versus those who screened negative demonstrated statistically significant differences in gender (p = 0.0046), age (p<0.0001), BMI (p = 0.0307), smoking status (p<0.0001), employment status (p<0.0001) and income (p = 0.0321). CONCLUSIONS: The prevalence of HS in Australia was estimated to be 0.67% (95% CI 0.53%-0.84%). The diagnosis rate amongst the suspected HS cases was low, which appeared to be due to a combination of patients not seeking help and decentralization of care. Individuals suspected of having HS were more likely to be females, young, obese, smokers, unemployed or at home duties and having lower annual personal income in comparison with individuals not suspected of having HS. Public Library of Science 2018-07-24 /pmc/articles/PMC6057625/ /pubmed/30040827 http://dx.doi.org/10.1371/journal.pone.0200683 Text en © 2018 Calao et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Calao, Miriam
Wilson, Jodie L.
Spelman, Lynda
Billot, Laurent
Rubel, Diana
Watts, Alan D.
Jemec, Gregor B. E.
Hidradenitis Suppurativa (HS) prevalence, demographics and management pathways in Australia: A population-based cross-sectional study
title Hidradenitis Suppurativa (HS) prevalence, demographics and management pathways in Australia: A population-based cross-sectional study
title_full Hidradenitis Suppurativa (HS) prevalence, demographics and management pathways in Australia: A population-based cross-sectional study
title_fullStr Hidradenitis Suppurativa (HS) prevalence, demographics and management pathways in Australia: A population-based cross-sectional study
title_full_unstemmed Hidradenitis Suppurativa (HS) prevalence, demographics and management pathways in Australia: A population-based cross-sectional study
title_short Hidradenitis Suppurativa (HS) prevalence, demographics and management pathways in Australia: A population-based cross-sectional study
title_sort hidradenitis suppurativa (hs) prevalence, demographics and management pathways in australia: a population-based cross-sectional study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057625/
https://www.ncbi.nlm.nih.gov/pubmed/30040827
http://dx.doi.org/10.1371/journal.pone.0200683
work_keys_str_mv AT calaomiriam hidradenitissuppurativahsprevalencedemographicsandmanagementpathwaysinaustraliaapopulationbasedcrosssectionalstudy
AT wilsonjodiel hidradenitissuppurativahsprevalencedemographicsandmanagementpathwaysinaustraliaapopulationbasedcrosssectionalstudy
AT spelmanlynda hidradenitissuppurativahsprevalencedemographicsandmanagementpathwaysinaustraliaapopulationbasedcrosssectionalstudy
AT billotlaurent hidradenitissuppurativahsprevalencedemographicsandmanagementpathwaysinaustraliaapopulationbasedcrosssectionalstudy
AT rubeldiana hidradenitissuppurativahsprevalencedemographicsandmanagementpathwaysinaustraliaapopulationbasedcrosssectionalstudy
AT wattsaland hidradenitissuppurativahsprevalencedemographicsandmanagementpathwaysinaustraliaapopulationbasedcrosssectionalstudy
AT jemecgregorbe hidradenitissuppurativahsprevalencedemographicsandmanagementpathwaysinaustraliaapopulationbasedcrosssectionalstudy